デフォルト表紙
市場調査レポート
商品コード
1613235

カスタム抗体市場:タイプ別、サービス別、供給源別、調査分野別、エンドユーザー別、用途別-2025-2030年世界予測

Custom Antibody Market by Type, Service, Source, Research Area, End Users, Application - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 190 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.81円
カスタム抗体市場:タイプ別、サービス別、供給源別、調査分野別、エンドユーザー別、用途別-2025-2030年世界予測
出版日: 2024年12月01日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

カスタム抗体市場は、2023年に7億5,586万米ドルと評価され、2024年には8億7,188万米ドルに達すると予測され、CAGR 16.10%で成長し、2030年には21億4,990万米ドルに達すると予測されています。

カスタム抗体市場は、研究、診断、治療における多様な用途のために、特定の抗原またはエピトープに合わせた抗体の開発と販売によって定義されます。カスタム抗体の必要性は、免疫学、腫瘍学、神経生物学などの分野で重要な標的タンパク質の特異性と検出感度を提供する能力に由来します。調査用途には、ELISA、ウェスタンブロッティング、免疫組織化学、フローサイトメトリーなどがあり、製薬会社、学術研究機関、診断ラボなどの最終用途分野に使用されています。市場開拓の主な要因は、慢性疾患の有病率の上昇、研究開発投資の増加、バイオテクノロジー企業と研究機関の共同研究の増加です。この市場における最新のビジネスチャンスとしては、高親和性抗体を迅速に開発する能力を高めるファージディスプレイや次世代シーケンシングなどの抗体探索技術の進歩が挙げられます。市場関係者は戦略的提携を結び、新興市場への進出に注力することで、こうした機会を捉えることができます。しかし、市場は高い初期生産コストや厳しい規制要件など、成長の妨げとなる課題に直面しています。さらに、継続的なイノベーションを必要とする激しい競合も存在します。このような課題にもかかわらず、多特異性抗体薬物複合体の開発における技術革新は有利な機会をもたらします。二重特異性抗体やナノボディーのような分野への調査拡大は、大きな成長の道を提供する可能性があります。市場の競合情勢を考察すると、強固な抗体探索プラットフォームの開発に重点が置かれており、競争は激しいです。市場の性質は研究集約的でダイナミックであり、絶え間ない進歩が機会と課題の両方を提供しています。そのため、企業は高度な研究技術に投資し、新たな市場の需要に適応し、持続的な成長のために最先端の科学的進歩を活用するために、機敏なオペレーションを維持することが推奨されます。

主な市場の統計
基準年[2023] 7億5,586万米ドル
推定年[2024] 8億7,188万米ドル
予測年[2030] 21億4,990万米ドル
CAGR(%) 16.10%

市場力学:急速に進化するカスタム抗体市場の主要市場インサイトを公開

カスタム抗体市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 慢性感染症の世界の流行
    • 研究、診断、治療におけるカスタム抗体の応用拡大
    • 抗体工学および個別化治療における先端技術の採用増加
  • 市場抑制要因
    • カスタム抗体の開発に多大な時間と労力を要すること
  • 市場機会
    • 政府および民間セクターによるライフサイエンスおよび臨床研究への戦略的投資
    • 抗体治療薬の増加と医薬品パイプラインの拡大
  • 市場の課題
    • 代替抗体の存在

ポーターのファイブフォースカスタム抗体市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:カスタム抗体市場における外部からの影響の把握

外部マクロ環境要因は、カスタム抗体市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析カスタム抗体市場における競合情勢の把握

カスタム抗体市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスカスタム抗体市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、カスタム抗体市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨カスタム抗体市場における成功への道筋を描く

カスタム抗体市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 慢性感染症の蔓延が世界中で増加
      • 調査、診断、治療にわたるカスタム抗体の応用の拡大
      • 抗体工学と個別化治療における先進技術の採用増加
    • 抑制要因
      • カスタム抗体の開発には多大な時間と労力がかかる
    • 機会
      • 政府と民間セクターは生命科学と臨床調査に戦略的に投資する
      • 抗体治療薬の増加と医薬品パイプラインの拡大
    • 課題
      • 代替抗体の存在
  • 市場セグメンテーション分析
    • タイプ:重篤な疾患に対処するためのモノクローナル抗体の新たな必要性
    • エンドユーザー:医薬品・バイオテクノロジー企業による医薬品開発および診断への投資拡大
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 カスタム抗体市場:タイプ別

  • モノクローナル抗体
  • ポリクローナル抗体
  • 組み換え抗体

第7章 カスタム抗体市場:サービス別

  • 抗体開発
  • 抗体の断片化と標識
  • 抗体の生産と精製

第8章 カスタム抗体市場:ソース別

  • マウス
  • うさぎ

第9章 カスタム抗体市場調査分野別

  • 心血管疾患
  • 免疫学
  • 感染症
  • 神経生物学
  • 腫瘍学
  • 幹細胞

第10章 カスタム抗体市場:エンドユーザー別

  • 学術調査機関
  • 契約調査機関
  • 病院・クリニック
  • 製薬・バイオテクノロジー企業

第11章 カスタム抗体市場:用途別

  • 調査
  • 治療薬

第12章 南北アメリカのカスタム抗体市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第13章 アジア太平洋地域のカスタム抗体市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第14章 欧州・中東・アフリカのカスタム抗体市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第15章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • ダナハー、抗体サプライヤーのアブカムを57億米ドルで買収へ
    • メルク、108億米ドルの買収でmAbを開発へ
    • セルトリオンとジェヌーブが新たな治療用抗体の開発で提携
  • 戦略分析と提言

企業一覧

  • Abbiotec, Inc.
  • Abcam PLC
  • ABclonal, Inc.
  • Abgenex Pvt. Ltd.
  • Abnova Corporation
  • Acrobiosystems Inc.
  • Agilent Technologies, Inc.
  • Alta Bioscience Limited
  • Bio Basic Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • BioChain Incorporated
  • Bioklone Biotech Private Limited
  • BioLegend, Inc. by PerkinElmer, Inc.
  • Biosynth Ltd.
  • Boster Biological Technology
  • BTL Biotechno Labs Private Limited
  • Capralogics, Inc.
  • Cell Signaling Technology, Inc.
  • CiteAb Limited
  • Creative Biolabs
  • Creative Diagnostics
  • CSBio(Shanghai)Ltd.
  • Cusabio Technology LLC
  • Davids Biotechnologie GmbH
  • Elabscience
  • evitria AG by Atlas Antibiodies
  • GenScript Biotech Corporation
  • Imgenex India Pvt. Ltd.
  • Innovagen AB
  • Inotiv, Inc.
  • Kaneka Eurogentec S.A.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Metabion International AG
  • MyBiosource, Inc.
  • OriGene Technologies, Inc.
  • Oy Medix Biochemica AB
  • Pacific Immunology
  • PhosphoSolutions
  • ProMab Biotechnologies, Inc.
  • ProSci Incorporated
  • ProteoGenix SA
  • RayBiotech Life, Inc.
  • Rockland Immunochemicals, Inc.
  • Sino Biological, Inc.
  • The Antibody Company
  • Thermo Fisher Scientific, Inc.
  • YenZym Antibodies, LLC
図表

LIST OF FIGURES

  • FIGURE 1. CUSTOM ANTIBODY MARKET RESEARCH PROCESS
  • FIGURE 2. CUSTOM ANTIBODY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CUSTOM ANTIBODY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. CUSTOM ANTIBODY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. CUSTOM ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CUSTOM ANTIBODY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CUSTOM ANTIBODY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CUSTOM ANTIBODY MARKET DYNAMICS
  • TABLE 7. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RECOMBINANT ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ANTIBODY DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ANTIBODY FRAGMENTATION & LABELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ANTIBODY PRODUCTION & PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY MICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RABBIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY NEUROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. CUSTOM ANTIBODY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. CUSTOM ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-46132FF79A8E

The Custom Antibody Market was valued at USD 755.86 million in 2023, expected to reach USD 871.88 million in 2024, and is projected to grow at a CAGR of 16.10%, to USD 2,149.90 million by 2030.

The custom antibody market is defined by the development and sale of antibodies tailored to specific antigens or epitopes for a diverse range of applications in research, diagnostics, and therapeutics. The necessity for custom antibodies stems from their ability to provide specificity and sensitivity in detecting target proteins, which is crucial in fields such as immunology, oncology, and neurobiology. Applications include use in ELISA, western blotting, immunohistochemistry, and flow cytometry, serving end-use sectors like pharmaceutical companies, academic research institutions, and diagnostic labs. Market growth is primarily driven by the rising prevalence of chronic diseases, increasing investment in research and development, and the growing number of collaborations between biotech firms and research institutes. The latest opportunities in this market include the advancement of antibody discovery technologies such as phage display and next-generation sequencing which enhance the ability to develop high-affinity antibodies swiftly. Market players are encouraged to form strategic alliances and focus on expansion into emerging markets to seize these opportunities. However, the market faces challenges including high initial production costs and stringent regulatory requirements which can hinder growth. Additionally, there is intense competition which necessitates continuous innovation. Despite these challenges, innovation in the development of multi-specific and antibody-drug conjugates presents lucrative opportunities. Expanding research into areas such as bispecific antibodies and nanobodies can offer significant growth avenues. Insight into the market indicates a highly competitive landscape with a strong focus on developing robust antibody discovery platforms. The market's nature is research-intensive and dynamic, with continuous advancements offering both opportunities and challenges. As such, businesses are recommended to invest in advanced research technologies and maintain agile operations to adapt to new market demands and leverage cutting-edge scientific advancements for sustained growth.

KEY MARKET STATISTICS
Base Year [2023] USD 755.86 million
Estimated Year [2024] USD 871.88 million
Forecast Year [2030] USD 2,149.90 million
CAGR (%) 16.10%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Custom Antibody Market

The Custom Antibody Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of chronic infectious disease worldwide
    • Expanding applications of custom antibody across research, diagnostics, and therapeutics
    • Rising adoption of advanced technologies in antibody engineering and personalized therapeutics
  • Market Restraints
    • Extensive and time consuming to develop custom antibodies
  • Market Opportunities
    • Governments and private sector strategically investments in life science and clinical research
    • Increase in therapeutics of antibodies and expansion of drug pipeline
  • Market Challenges
    • Presence of alternative antibodies

Porter's Five Forces: A Strategic Tool for Navigating the Custom Antibody Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Custom Antibody Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Custom Antibody Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Custom Antibody Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Custom Antibody Market

A detailed market share analysis in the Custom Antibody Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Custom Antibody Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Custom Antibody Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Custom Antibody Market

A strategic analysis of the Custom Antibody Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Custom Antibody Market, highlighting leading vendors and their innovative profiles. These include Abbiotec, Inc., Abcam PLC, ABclonal, Inc., Abgenex Pvt. Ltd., Abnova Corporation, Acrobiosystems Inc., Agilent Technologies, Inc., Alta Bioscience Limited, Bio Basic Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BioChain Incorporated, Bioklone Biotech Private Limited, BioLegend, Inc. by PerkinElmer, Inc., Biosynth Ltd., Boster Biological Technology, BTL Biotechno Labs Private Limited, Capralogics, Inc., Cell Signaling Technology, Inc., CiteAb Limited, Creative Biolabs, Creative Diagnostics, CSBio (Shanghai) Ltd., Cusabio Technology LLC, Davids Biotechnologie GmbH, Elabscience, evitria AG by Atlas Antibiodies, GenScript Biotech Corporation, Imgenex India Pvt. Ltd., Innovagen AB, Inotiv, Inc., Kaneka Eurogentec S.A., Laboratory Corporation of America Holdings, Merck KGaA, Metabion International AG, MyBiosource, Inc., OriGene Technologies, Inc., Oy Medix Biochemica AB, Pacific Immunology, PhosphoSolutions, ProMab Biotechnologies, Inc., ProSci Incorporated, ProteoGenix SA, RayBiotech Life, Inc., Rockland Immunochemicals, Inc., Sino Biological, Inc., The Antibody Company, Thermo Fisher Scientific, Inc., and YenZym Antibodies, LLC.

Market Segmentation & Coverage

This research report categorizes the Custom Antibody Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Monoclonal Antibodies, Polyclonal Antibodies, and Recombinant Antibodies.
  • Based on Service, market is studied across Antibody Development, Antibody Fragmentation & Labeling, and Antibody Production & Purification.
  • Based on Source, market is studied across Mice and Rabbit.
  • Based on Research Area, market is studied across Cardiovascular Diseases, Immunology, Infectious Diseases, Neurobiology, Oncology, and Stem cells.
  • Based on End Users, market is studied across Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.
  • Based on Application, market is studied across Research and Therapeutics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of chronic infectious disease worldwide
      • 5.1.1.2. Expanding applications of custom antibody across research, diagnostics, and therapeutics
      • 5.1.1.3. Rising adoption of advanced technologies in antibody engineering and personalized therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. Extensive and time consuming to develop custom antibodies
    • 5.1.3. Opportunities
      • 5.1.3.1. Governments and private sector strategically investments in life science and clinical research
      • 5.1.3.2. Increase in therapeutics of antibodies and expansion of drug pipeline
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of alternative antibodies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Emerging need for monoclonal antibodies to tackle severe disease states
    • 5.2.2. End Users: Expanding investments by the pharmaceutical & biotechnology companies in drug development and diagnostics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Custom Antibody Market, by Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Polyclonal Antibodies
  • 6.4. Recombinant Antibodies

7. Custom Antibody Market, by Service

  • 7.1. Introduction
  • 7.2. Antibody Development
  • 7.3. Antibody Fragmentation & Labeling
  • 7.4. Antibody Production & Purification

8. Custom Antibody Market, by Source

  • 8.1. Introduction
  • 8.2. Mice
  • 8.3. Rabbit

9. Custom Antibody Market, by Research Area

  • 9.1. Introduction
  • 9.2. Cardiovascular Diseases
  • 9.3. Immunology
  • 9.4. Infectious Diseases
  • 9.5. Neurobiology
  • 9.6. Oncology
  • 9.7. Stem cells

10. Custom Antibody Market, by End Users

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Contract Research Organizations
  • 10.4. Hospitals & Clinics
  • 10.5. Pharmaceutical & Biotechnology Companies

11. Custom Antibody Market, by Application

  • 11.1. Introduction
  • 11.2. Research
  • 11.3. Therapeutics

12. Americas Custom Antibody Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Custom Antibody Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Custom Antibody Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Danaher to Buy Antibody Supplier Abcam for USD 5.7 Billion
    • 15.3.2. Merck to Develop mAb Through USD 10.8 Billion Acquisition
    • 15.3.3. Celltrion and Genuv Partner to Develop Novel Therapeutic Antibodies
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbiotec, Inc.
  • 2. Abcam PLC
  • 3. ABclonal, Inc.
  • 4. Abgenex Pvt. Ltd.
  • 5. Abnova Corporation
  • 6. Acrobiosystems Inc.
  • 7. Agilent Technologies, Inc.
  • 8. Alta Bioscience Limited
  • 9. Bio Basic Inc.
  • 10. Bio-Rad Laboratories, Inc.
  • 11. Bio-Techne Corporation
  • 12. BioChain Incorporated
  • 13. Bioklone Biotech Private Limited
  • 14. BioLegend, Inc. by PerkinElmer, Inc.
  • 15. Biosynth Ltd.
  • 16. Boster Biological Technology
  • 17. BTL Biotechno Labs Private Limited
  • 18. Capralogics, Inc.
  • 19. Cell Signaling Technology, Inc.
  • 20. CiteAb Limited
  • 21. Creative Biolabs
  • 22. Creative Diagnostics
  • 23. CSBio (Shanghai) Ltd.
  • 24. Cusabio Technology LLC
  • 25. Davids Biotechnologie GmbH
  • 26. Elabscience
  • 27. evitria AG by Atlas Antibiodies
  • 28. GenScript Biotech Corporation
  • 29. Imgenex India Pvt. Ltd.
  • 30. Innovagen AB
  • 31. Inotiv, Inc.
  • 32. Kaneka Eurogentec S.A.
  • 33. Laboratory Corporation of America Holdings
  • 34. Merck KGaA
  • 35. Metabion International AG
  • 36. MyBiosource, Inc.
  • 37. OriGene Technologies, Inc.
  • 38. Oy Medix Biochemica AB
  • 39. Pacific Immunology
  • 40. PhosphoSolutions
  • 41. ProMab Biotechnologies, Inc.
  • 42. ProSci Incorporated
  • 43. ProteoGenix SA
  • 44. RayBiotech Life, Inc.
  • 45. Rockland Immunochemicals, Inc.
  • 46. Sino Biological, Inc.
  • 47. The Antibody Company
  • 48. Thermo Fisher Scientific, Inc.
  • 49. YenZym Antibodies, LLC